Abstract Details

Title Prevalence and Characteristics of Women with Menstrual Migraine in the 2021 United States National Health & Wellness Survey

Topic Headache

Presentation(s) S22 - Advances in Migraine and Therapeutics (1:12 PM-1:24 PM)

Poster/Presentation
Number 002

Objective To estimate the prevalence of menstrual migraine (MM) and describe characteristics of women with MM.

Background MM prevalence ranges from 10-to-70% depending on the population studied and there is a lack of evidence on current treatments.

Design/Methods This retrospective cross-sectional study used the 2021 US National Health and Wellness Survey (NHWS, Cerner Enviza) and captured women with diagnosed migraine who reported their migraines were associated with menses. MM prevalence was calculated among all women and among pre-menopausal women (18-39 years-old or 40-55 years-old with regular or irregular menstrual bleeding). Respondents reported their current migraine treatments, migraine frequency, and disability via The Migraine Disability Assessment Test (MIDAS).

Results Over 19.8 million women with diagnosed migraine were represented by the weighted survey and 11.8 million were pre-menopausal. MM was reported by 6.2 million women, with a prevalence of 31.0% among all women and 52.5% among pre-menopausal women. The mean age of women with MM was 33.2±9.5 years, 52.6% were married/partnered, 66.6% were employed, and 38.2% were obese. The reported monthly migraine attack frequency was 4.5±6.5 and monthly migraine headache days were 8.4±7.4 days on average. The mean MIDAS score was 24.8±34.8 and 56.2% had moderate-to-severe migraine-specific disability. Treatments among women with MM included 42.4% using only over-the-counter medications and 48.6% using prescription medications. Among these, 63.9% reported only acute migraine treatments and 21.1% reported any use of migraine prevention. The most common acute treatments were triptans (36.7%; 3.9±5.2 days of use), non-steroidal anti-inflammatory drugs (31.1%; 8.1±8.2 days), and opioids (22.2%; 7.9±8.4 days).

Conclusions The prevalence of MM was 31-52% among women and more than half of women with MM reported moderate-to-severe disability associated with their migraines. Acute medication use was common, including 42.4% who reported managing with non-prescription acute treatments and low overall use of preventative therapies (21.1%).

Authors/Disclosures
Jessica Cirillo (Pfizer) PRESENTER	Mrs. Cirillo has received personal compensation for serving as an employee of Pfizer. Mrs. Cirillo has stock in Pfizer.
Joshua Brown, PhD (Pfizer, Inc.)	Dr. Brown has received personal compensation for serving as an employee of Pfizer, Inc..
Motomori Lewis (Pfizer)	Motomori Lewis has received personal compensation for serving as an employee of Pfizer.
Aaron Jenkins	Aaron Jenkins has received personal compensation for serving as an employee of Pfizer Ltd. Aaron Jenkins has stock in Pfizer Ltd.
Karin Hygge Blakeman	Karin Hygge Blakeman has received personal compensation for serving as an employee of Pfizer. Karin Hygge Blakeman has stock in Pfizer.
Jerry Yang (Pfizer Inc.)	Jerry Yang has received personal compensation for serving as an employee of Pfizer Inc. Jerry Yang has stock in Pfizer Inc.
Lucy Abraham	Lucy Abraham has received personal compensation for serving as an employee of Pfizer R&D UK Ltd. Lucy Abraham has stock in Pfizer R&D UK Ltd.
Jessica Ailani, MD, FAAN (Medstar Georgetown Neurology)	Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ipsen. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merz. Dr. Ailani has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Aspeya. Dr. Ailani has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bausch. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Ailani has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Kallyope. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TCG Soleil Lab. Dr. Ailani has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Shira Tronic. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Azurity. Dr. Ailani has or had stock in Minded. The institution of Dr. Ailani has received research support from Ipsen. The institution of Dr. Ailani has received research support from Lundbeck. The institution of Dr. Ailani has received research support from Merz. The institution of Dr. Ailani has received research support from Pfizer. Dr. Ailani has received research support from Mi-Helper. The institution of Dr. Ailani has received research support from ShiraTronic. The institution of Dr. Ailani has received research support from Salvia. Dr. Ailani has a non-compensated relationship as a Executive Board Member with American Headache Society that is relevant to AAN interests or activities.

��ɫ��

��ɫ��